2m 2m 2m 2m 2m 2m 2m
Regenicin (RGIN)
OTC
$0.000001$0.00 (0.00%)
Price as of Mar 30, 2026- $15,348.00Market Cap
- -99.00%1-Year Change
- BiotechnologyIndustry
Regenicin (RGIN)
$0.000001$0.00 (0.00%)
Annual
Quarterly
09/30/2022 | 09/30/2021 | 09/30/2020 | ||
|---|---|---|---|---|
Income Statement | ||||
Total Operating Revenue | 1,825 +7,200.00% | 25 +101.45% | -1,725 N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 1,825 +7,200.00% | 25 +101.45% | -1,725 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | N/A N/A | N/A N/A | N/A N/A | |
Depreciation and Amortization Expense | N/A N/A | N/A N/A | N/A N/A | |
Total Operating Expenses | 601,179 -5.45% | 635,864 -4.20% | 663,749 N/A | |
Operating Profit | -639,262 +0.53% | -635,864 +24.48% | -510,816 N/A | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -36,258 +4.45% | -34,713 -26.22% | -47,050 N/A | |
Interest Income and Expense and Net | -36,258 +4.45% | -34,713 -26.22% | -47,050 N/A | |
Total Nonoperating Income and Expense | -36,258 +4.45% | -34,713 -173.78% | 47,050 N/A | |
Income before Taxes | -692,216 -6.58% | -741,007 +17.51% | -630,583 N/A | |
Income Taxes | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -639,262 -4.67% | -670,602 -219.84% | 559,591 N/A | |
Net Income from Continuing Operations Applicable to Common | -692,216 -6.58% | -741,007 +17.51% | -630,583 N/A | |
Basic EPS and Net Income | N/A N/A | N/A N/A | N/A N/A | |
Diluted EPS and Net Income | N/A N/A | N/A N/A | N/A N/A | |
Basic Weighted Average Shares | 153.5M 0.00% | 153.5M 0.00% | 153.5M N/A | |
Diluted Weighted Average Shares | 153.5M 0.00% | 153.5M 0.00% | 153.5M N/A | |
Balance Sheet | ||||
Cash and Cash Equivalents | 14,569 +683.70% | 1,859 +36.09% | 1,366 N/A | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 14,569 +683.70% | 1,859 +36.09% | 1,366 N/A | |
Total Current Assets | 14,568 +683.65% | 1,859 +36.09% | 1,366 N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Assets | N/A N/A | N/A N/A | N/A N/A | |
Total Assets | 15,493 +236.15% | 4,609 +11.30% | 4,141 N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 520,683 0.00% | 520,683 0.00% | 520,683 N/A | |
Total Current Liabilities | 5.6M +13.10% | 5.0M +15.64% | 4.3M N/A | |
Total Long-Term Debt | 335,683 0.00% | 335,683 0.00% | 335,683 N/A | |
Total Long-Term Liabilities | N/A N/A | N/A N/A | N/A N/A | |
Total Liabilities | 5.6M +13.10% | 5.0M +15.64% | 4.3M N/A | |
Retained Earnings | 16.0M +4.17% | 15.3M +204.58% | -14.6M N/A | |
Total Stockholders Equity | -5.6M +12.89% | -5.0M +15.64% | -4.3M N/A | |
Total Shares Outstanding | 153.5M 0.00% | 153.5M 0.00% | 153.5M N/A | |
Cash Flow | ||||
Cash from Operating Activities | -27,291 +13.21% | -24,107 -80.43% | -123,199 N/A | |
Capital Expenditures | N/A N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | N/A N/A | N/A N/A | N/A N/A | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 40,000 +62.60% | 24,600 -80.12% | 123,750 N/A | |
Financials Ratio | ||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -35,028.05% -98.62% | -2,543,456.00% -8,689.12% | 29,612.52% N/A | |
Return on Assets | -6,360.18% -58.51% | -15,328.05% -229.51% | 11,835.68% N/A | |
Return on Equity | 12.11% -16.50% | 14.51% +203.89% | -13.96% N/A | |
Revenue Growth | 7,200.00% +6,997.14% | 101.45% +80.10% | 56.33% N/A | |
Current Ratio | 0.003 +550.00% | 0.0004 +33.33% | 0.0003 N/A | |
Cash Ratio | 0.003 +550.00% | 0.0004 +33.33% | 0.0003 N/A | |
Debt-to-Equity Ratio | -0.15 -11.41% | -0.17 -13.52% | -0.20 N/A | |
Debt-to-Assets Ratio | 55.27 -70.25% | 185.80 -10.15% | 206.80 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow